Molecular Targeting of ERKs/RSK2 Signaling in Cancers

Author(s): Yong-Yeon Cho*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 29 , 2017


Become EABM
Become Reviewer
Call for Editor

Abstract:

Accumulating studies have provided concrete evidence that p90 ribosomal S6 kinase 2 (RSK2) is a key signaling molecule involved in cell proliferation, transformation, and cancer development. RSK2 is known to be an etiological gene of Coffin-Lowry Syndrome (CLS). Recently, signaling analysis and molecular biological approaches have provided concrete evidence that RSK2 plays an essential role in human cancers. Here, we will extensively discuss signaling pathways regulating RSK2 activity, the role of RSK2 in human cancer development, inhibitors suppressing RSK2 activity, and why RSK2 is an important target to develop drugs for human cancers.

Keywords: Ras signaling pathway, ERK/RSK2, cell proliferation, carcinogenesis, cancer, emerging target.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 23
ISSUE: 29
Year: 2017
Published on: 14 July, 2017
Page: [4247 - 4258]
Pages: 12
DOI: 10.2174/1381612823666170714142338
Price: $65

Article Metrics

PDF: 33
HTML: 5
EPUB: 1